Creutzfeldt Jakob Disease Market Research Report – Forecast to 2027

Global Creutzfeldt-Jakob Disease (CJD) Market Research Report, by type (Sporadic CJD, Hereditary CJD), diagnosis (imaging, brain biopsy), treatment (opiate drugs, clonazepam, sodium valproate), end users (hospitals, clinics) - global forecast till 2027

ID: MRFR/Pharma/4419-HCR | February 2021 | Region: Global | 100 pages

Please note that the assessment period of report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario:


Creutzfeldt-Jakob disease or CJD is a rare, degenerative brain disorder which may lead to dementia and sudden death. The early stage symptoms of the disease include failing memory and lack of coordination followed by visual disturbances. As the disease progresses, mental deterioration becomes prominent leading to weakness of extremities, and conditions like coma. The CJD disease can be classified into three major groups, namely sporadic CJD, hereditary CJD, and acquired CJD. Sporadic CJD is the most common form of the disease and accounts for approximately 85% of the total reported cases. A majority of the treatments available in the market are symptomatic and aimed at alleviating pain.   The risk factors for the development of the disease are inclusive of old age, familial CJD genetics, and others. Increasing prevalence of Creutzfeldt-Jakob disease and growing geriatric population are estimated to be the major drivers for the market growth during the forecast period. In 2017, the National Institute of Neurological Disorders and Stroke stated that approximately 300 new cases of CJD are reported every year within the U.S. Moreover, it has been estimated that the symptomatic onset of the medical condition occurs predominantly around the age of 60. Additionally, according to the United States Census Bureau, the global geriatric population is projected to more than double and reach 1.6 billion from 2025 to 2050. Additionally, factors such as increasing per capita healthcare expenditure and extensive research and development by the market players will drive the market growth. However, lack of awareness, limited availability of therapeutics, and erroneous diagnostic results are estimated to restrain the market growth during the forecast period.


The global Creutzfeldt-Jakob disease (CJD) market is expected to grow at an approximate CAGR of 17.5% during forecast period.


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers


Figure 1- Global Creutzfeldt-Jakob Disease (CJD) Market Share, by Region


 Creutzfeldt-Jakob Disease (CJD) Market


Sources: National Institute of Neurological Disorders and Stroke, United States Census Bureau, Age UK, Indian Brand Equity Foundation, annual reports, press release, white paper, and company presentation


Segmentation


The global Creutzfeldt-Jakob disease (CJD) market is segmented on the basis of type, diagnosis, treatment, and end user.


On the basis of the type, the market is segmented into sporadic CJD, hereditary CJD, and acquired CJD. On the basis of the diagnosis, the market is categorized into imaging, spinal fluid tests, brain biopsy, and others. The imaging segment is sub-segmented into electroencephalogram (EEG), magnetic resonance imaging (MRI), computerized tomography (CT), and others. On the basis of the treatment, the market is segmented into opiate drugs, clonazepam, sodium valproate, and others.  On the basis of the end users, the market is segmented into hospitals & clinics, research organizations, diagnostic centers, medical research institutes, and others.


Research Methodology


 Creutzfeldt-Jakob Disease (CJD) Methodology


Sources: National Institute of Neurological Disorders and Stroke, United States Census Bureau, Age UK, Indian Brand Equity Foundation, annual reports, press release, white paper, and company presentation


Regional Analysis


The Americas dominate the global market for Creutzfeldt-Jakob disease (CJD) market due to a huge patient population, presence of a well-developed healthcare sector, and market key players like Mylan N.V., GENERAL ELECTRIC, Apotex Inc., and others within the region. Moreover, changing lifestyle and growing healthcare expenditure fuels the market within the regional boundaries of the Americas.


Europe is second in the global Creutzfeldt-Jakob disease (CJD) market owing to the availability of funds for research and development and growing geriatric population. In 2018, according to the Age UK, there are approximately 11.8 million people aged 65 or above within U.K. Regionally, Europe is divided into Western Europe and Eastern Europe. Western Europe leads the market due to the presence of developed economies like Italy, U.K, France, and others.


Asia Pacific is estimated to be the fastest growing region for the global Creutzfeldt-Jakob disease (CJD) market. This can be attributed due to the increasing geriatric population and a continuously developing healthcare sector within the region.  According to the Indian Brand Equity Foundation in 2016, the Indian healthcare sector was projected to be one of the fastest growing industries. The healthcare sector in India is expected to grow at a CAGR of 22.87% from 2015 to 2020, reaching USD 280 billion by 2020.


On the other hand, the Middle East & Africa holds the least share in the global Creutzfeldt-Jakob disease (CJD) market due to the presence of poor economies, and stringent government policies, especially within the African region. A majority of the Middle East & African region is estimated to be held by the Middle East due to the presence of developed economies like Kuwait, Qatar, Dubai, and others.


Key players


Some of the key players for the global Creutzfeldt-Jakob disease (CJD) market are Teva Pharmaceutical Industries Ltd. (Israel), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V.  (U.S.), Sandoz International GmbH (Germany), Sun Pharmaceutical Industries Ltd. (India), Apotex Inc. (Canada), Par Pharmaceutical. (U.S.), GENERAL ELECTRIC (U.S.), Koninklijke Philips N.V. (The Netherlands), Medtronic (U.S.), Siemens AG (Germany), Accuray Incorporated (U.S.), and others.



Frequently Asked Questions (FAQ) :


Creutzfeldt-Jakob disease or CJD is a rare, degenerative brain disorder which may lead to dementia and sudden death.

Global Creutzfeldt-Jakob disease market is expected to exhibit a strong 17.5% CAGR over the forecast period till 2027.

The growing geriatric population is the major driver for the Creutzfeldt-Jakob disease market.

The Americas dominate the global Creutzfeldt-Jakob disease market.

Leading players in the Creutzfeldt-Jakob disease market include Teva Pharmaceutical Industries, Mylan NV, and General Electric, among others.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Creutzfeldt-Jakob Disease (CJD) Market, by Type

6.1 Introduction

6.2 Sporadic CJD

Market Estimates & Forecast, 2020 – 2027

6.3 Hereditary CJD

Market Estimates & Forecast, 2020 – 2027

6.4 Acquired CJD

Market Estimates & Forecast, 2020 – 2027

Chapter 7. Global Creutzfeldt-Jakob Disease (CJD) Market, by Diagnosis

7.1 Introduction

7.2 By Imaging

Market Estimates & Forecast, 2020 – 2027

7.2.1 Electroencephalogram (EEG)

7.2.2 Magnetic Resonance Imaging (MRI)

7.2.3 Computerized Tomography (CT)

7.2.4 Others

7.3 Spinal Fluid Tests

Market Estimates & Forecast, 2020 – 2027

7.4 Brain Biopsy

Market Estimates & Forecast, 2020 – 2027

7.5 Others

Chapter 8. Global Creutzfeldt-Jakob Disease (CJD) Market, by Treatment

8.1 Introduction

8.2 Opiate Drugs

Market Estimates & Forecast, 2020 – 2027

8.3 Clonazepam

Market Estimates & Forecast, 2020 – 2027

8.4 Sodium valproate

Market Estimates & Forecast, 2020 – 2027

8.5 Others

Chapter 9. Global Creutzfeldt-Jakob Disease (CJD) Market, by End User

9.1 Introduction

9.2 Hospitals and Clinics

Market Estimates & Forecast, 2020 – 2027

9.3 Research Organizations

Market Estimates & Forecast, 2020 – 2027

9.4 Diagnostic Centers

Market Estimates & Forecast, 2020 – 2027

9.5 Medical Research Institutes

Market Estimates & Forecast, 2020 – 2027

9.6 Others

Chapter 10. Global Creutzfeldt-Jakob Disease (CJD) Market, by Region

10.1 Introduction

10.2 America

10.2.1 North America

10.2.1.1 U.S.

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

Chapter 12 Company Profiles

12.1 Teva Pharmaceutical Industries Ltd.

12.1.1 Company Overview

12.1.2 Type Overview

12.1.3 Financials

12.2.4 Key Developments

12.1.5 SWOT Analysis

12.2 F. Hoffmann-La Roche Ltd

12.2.1 Company Overview

12.2.2 Type Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Mylan N.V.

12.3.1 Company Overview

12.3.2 Type Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Sandoz International GmbH

12.4.1 Company Overview

12.4.2 Type/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Sun Pharmaceutical Industries Ltd.

12.5.1 Company Overview

12.5.2 Type Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 Apotex Inc.

12.6.1 Company Overview

12.6.2 Type Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Par Pharmaceutical.

12.7.1 Overview

12.7.2 Type Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 GENERAL ELECTRIC

12.8.1 Overview

12.8.2 Type Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 Koninklijke Philips N.V.

12.9.1 Overview

12.9.2 Type Overview

12.9.3 Financials

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.10 Medtronic

12.10.1 Overview

12.10.2 Type Overview

12.10.3 Financials

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.11 Siemens AG

12.11.1 Overview

12.11.2 Type Overview

12.11.3 Financials

12.11.4 Key Developments

12.11.5 SWOT Analysis

12.12 Accuray Incorporated

12.12.1 Overview

12.12.2 Type Overview

12.12.3 Financials

12.12.4 Key Developments

12.12.5 SWOT Analysis

12.13 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of global Creutzfeldt-Jakob disease (CJD) market

Chapter 14 Appendix

LIST OF TABLES

Table 1 Creutzfeldt-Jakob Disease (CJD) Market Industry Synopsis, 2020 – 2027

Table 2 Global Creutzfeldt-Jakob Disease (CJD) Market Estimates and Forecast, 2020 – 2027, (USD Million)

Table 3 Global Creutzfeldt-Jakob Disease (CJD) Market by Region, 2020 – 2027, (USD Million)

Table 4 Global Creutzfeldt-Jakob Disease (CJD) Market by Type, 2020 – 2027, (USD Million)

Table 5 Global Creutzfeldt-Jakob Disease (CJD) Market by Diagnosis, 2020 – 2027, (USD Million)

Table 6 Global Creutzfeldt-Jakob Disease (CJD) Market by Treatment, 2020 – 2027, (USD Million)

Table 7 Global Creutzfeldt-Jakob Disease (CJD) Market by End User, 2020 – 2027, (USD Million

Table 8 North America Creutzfeldt-Jakob disease (CJD) Market by Type, 2020 – 2027, (USD Million)

Table 9 North America Creutzfeldt-Jakob disease (CJD) Market by Diagnosis, 2020 – 2027, (USD Million)

Table 10 North America Creutzfeldt-Jakob disease (CJD) Market by Treatment, 2020 – 2027, (USD Million)

Table 11 North America Creutzfeldt-Jakob disease (CJD) Market by End User, 2020 – 2027, (USD Million)

Table 12 U.S. Creutzfeldt-Jakob disease (CJD) Market by Type, 2020 – 2027, (USD Million)

Table 13 U.S. Creutzfeldt-Jakob disease (CJD) Market by Diagnosis, 2020 – 2027, (USD Million)

Table 14 U.S. Creutzfeldt-Jakob disease (CJD) Market by Treatment, 2020 – 2027, (USD Million)

Table 15 U.S. Creutzfeldt-Jakob disease (CJD) Market by End User, 2020 – 2027, (USD Million)

Table 16 Canada Creutzfeldt-Jakob disease (CJD) Market by Type, 2020 – 2027, (USD Million)

Table 17 Canada Creutzfeldt-Jakob disease (CJD) Market by Diagnosis, 2020 – 2027, (USD Million)

Table 18 Canada Creutzfeldt-Jakob disease (CJD) Market by Treatment, 2020 – 2027, (USD Million)

Table 19 Canada Creutzfeldt-Jakob disease (CJD) Market by End User, 2020 – 2027, (USD Million)

Table 20 South America Creutzfeldt-Jakob disease (CJD) Market by Type, 2020 – 2027, (USD Million)

Table 21 South America Creutzfeldt-Jakob disease (CJD) Market by Diagnosis, 2020 – 2027, (USD Million)

Table 22 South America Creutzfeldt-Jakob disease (CJD) Market by Treatment, 2020 – 2027, (USD Million)

Table 23 South America Creutzfeldt-Jakob disease (CJD) Market by End User, 2020 – 2027, (USD Million)

Table 24 Europe Creutzfeldt-Jakob disease (CJD) Market by Type, 2020 – 2027, (USD Million)

Table 25 Europe Creutzfeldt-Jakob disease (CJD) Market by Diagnosis, 2020 – 2027, (USD Million)

Table 26 Europe Creutzfeldt-Jakob disease (CJD) Market by Treatment, 2020 – 2027, (USD Million)

Table 27 Europe Creutzfeldt-Jakob disease (CJD) Market by End User, 2020 – 2027, (USD Million)

Table 28 Western Europe Creutzfeldt-Jakob disease (CJD) Market by Type, 2020 – 2027, (USD Million)

Table 29 Western Europe Creutzfeldt-Jakob disease (CJD) Market by Diagnosis, 2020 – 2027, (USD Million)

Table 30 Western Europe Creutzfeldt-Jakob disease (CJD) Market by Treatment, 2020 – 2027, (USD Million)

Table 31 Western Europe Creutzfeldt-Jakob disease (CJD) Market by End User, 2020 – 2027, (USD Million)

Table 32 Eastern Europe Creutzfeldt-Jakob disease (CJD) Market by Type, 2020 – 2027, (USD Million)

Table 33 Eastern Europe Creutzfeldt-Jakob disease (CJD) Market by Diagnosis, 2020 – 2027, (USD Million)

Table 34 Eastern Europe Creutzfeldt-Jakob disease (CJD) Market by Treatment, 2020 – 2027, (USD Million)

Table 35 Eastern Europe Creutzfeldt-Jakob disease (CJD) Market by End User, 2020 – 2027, (USD Million)

Table 36 Asia Pacific Creutzfeldt-Jakob disease (CJD) Market by Type, 2020 – 2027, (USD Million)

Table 37 Asia Pacific Creutzfeldt-Jakob disease (CJD) Market by Diagnosis, 2020 – 2027, (USD Million)

Table 38 Asia Pacific Creutzfeldt-Jakob disease (CJD) Market by Treatment, 2020 – 2027, (USD Million)

Table 39 Asia Pacific Creutzfeldt-Jakob disease (CJD) Market by End User, 2020 – 2027, (USD Million)

Table 40 The Middle East & Africa Creutzfeldt-Jakob disease (CJD) Market by Type, 2020 – 2027, (USD Million)

Table 41 The Middle East & Africa Creutzfeldt-Jakob disease (CJD) Market by Diagnosis, 2020 – 2027, (USD Million)

Table 42 The Middle East & Africa Creutzfeldt-Jakob disease (CJD) Market by Treatment, 2020 – 2027, (USD Million)

Table 43 The Middle East & Africa Creutzfeldt-Jakob disease (CJD) Market by End User, 2020 – 2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Creutzfeldt-Jakob Disease (CJD) Market

Figure 3 Market Dynamics for Global Creutzfeldt-Jakob Disease (CJD) Market

Figure 4 Global Creutzfeldt-Jakob Disease (CJD) Market Share, by Type 2020

Figure 5 Global Creutzfeldt-Jakob Disease (CJD) Market Share, by Diagnosis 2020

Figure 6 Global Creutzfeldt-Jakob Disease (CJD) Market Share, by Treatment, 2020

Figure 7 Global Creutzfeldt-Jakob Disease (CJD) Market Share, by End User, 2020

Figure 8 Global Creutzfeldt-Jakob Disease (CJD) Market Share, by Region, 2020

Figure 9 North America Creutzfeldt-Jakob disease (CJD) Market Share, by Country, 2020

Figure 10 Europe Creutzfeldt-Jakob disease (CJD) Market Share, by Country, 2020

Figure 11 Asia Pacific Creutzfeldt-Jakob disease (CJD) Market Share, by Country, 2020

Figure 12 The Middle East & Africa Creutzfeldt-Jakob disease (CJD) Market Share, by Country, 2020

Figure 13 Global Creutzfeldt-Jakob Disease (CJD) Market: Company Share Analysis, 2020 (%)

Figure 14 Teva Pharmaceutical Industries Ltd.: Key Financials

Figure 15 Teva Pharmaceutical Industries Ltd.: Segmental Revenue

Figure 16 Teva Pharmaceutical Industries Ltd.: Geographical Revenue

Figure 17 F. Hoffmann-La Roche Ltd: Key Financials

Figure 18 F. Hoffmann-La Roche Ltd: Segmental Revenue

Figure 19 F. Hoffmann-La Roche Ltd: Geographical Revenue

Figure 20 Mylan N.V. : Key Financials

Figure 21 Mylan N.V. : Segmental Revenue

Figure 22 Mylan N.V. : Geographical Revenue

Figure 23 Sandoz International GmbH: Key Financials

Figure 24 Sandoz International GmbH: Segmental Revenue

Figure 25 Sandoz International GmbH: Geographical Revenue

Figure 26 Sun Pharmaceutical Industries Ltd.: Key Financials

Figure 27 Sun Pharmaceutical Industries Ltd.: Segmental Revenue

Figure 28 Sun Pharmaceutical Industries Ltd.: Geographical Revenue

Figure 29 Apotex Inc.: Key Financials

Figure 30 Apotex Inc.: Segmental Revenue

Figure 31 Apotex Inc.: Geographical Revenue

Figure 32 Par Pharmaceutical.: Key Financials

Figure 33 Par Pharmaceutical.: Segmental Revenue

Figure 34 Par Pharmaceutical.: Geographical Revenue

Figure 35 GENERAL ELECTRIC: Key Financials

Figure 36 GENERAL ELECTRIC: Segmental Revenue

Figure 37 GENERAL ELECTRIC: Geographical Revenue

Figure 38 Koninklijke Philips N.V.: Key Financials

Figure 39 Koninklijke Philips N.V.: Segmental Revenue

Figure 40 Koninklijke Philips N.V.: Geographical Revenue

Figure 41 Medtronic: Key Financials

Figure 42 Medtronic: Segmental Revenue

Figure 43 Medtronic: Geographical Revenue

Figure 44 Siemens AG: Key Financials

Figure 45 Siemens AG: Segmental Revenue

Figure 46 Siemens AG: Geographical Revenue

Figure 47 Accuray Incorporated: Key Financials

Figure 48 Accuray Incorporated: Segmental Revenue

Figure 49 Accuray Incorporated: Geographical Revenue